

UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

CURRICULUM VITAE

**Breelyn A. Wilky, MD**

Date: July 9, 2020

**Personal history**

Current Position: Associate Professor, Department of Medicine

Address: Anschutz Medical Campus  
12801 E. 17<sup>th</sup> Avenue, 8<sup>th</sup> Floor, Room 8117  
Mailstop 8117  
Aurora, CO 80045

Office Phone: (303) 724-6429  
Office Fax: (303) 724-3889  
Email: [Breelyn.Wilky@CUAnschutz.edu](mailto:Breelyn.Wilky@CUAnschutz.edu)

**Education**

08/1997 – 05/2001: Bates College, Lewiston, ME  
Degree – Bachelor of Science, *Cum Laude*  
Majors – Biology, Music (Honors)

08/2002 – 05/2006: University of Medicine and Dentistry of New Jersey –  
Robert Wood Johnson Medical School, Piscataway, NJ  
(now Rutgers Medical School)  
Degree – Doctor of Medicine with Distinction in Research

07/2006 – 06/2009 The Johns Hopkins Hospital, Baltimore, MD  
William Osler Internal Medicine Internship/Residency  
Certificate – Internal Medicine

07/2009 – 06/2013 Johns Hopkins University, Baltimore, MD  
Fellowship in Medical Oncology  
Certificate – Medical Oncology

**Academic appointments**

07/2006 – 06/2009 Intern and Resident, Internal Medicine  
The Johns Hopkins Hospital, Baltimore, MD  
Program Director: Charles Wiener, MD

07/2009 – 06/2010 Clinical Fellow, Medical Oncology  
Johns Hopkins University, Baltimore, MD  
Program Director: Ross Donehower, MD

07/2010 – 06/2013 Research Fellow, Medical Oncology  
Johns Hopkins University, Baltimore, MD

Program Director: Ross Donehower, MD  
Research Mentor: David M. Loeb, MD, PhD

07/2011 – 06/2012 Chief Fellow, Medical Oncology  
Johns Hopkins University, Baltimore, MD  
Program Director: Ross Donehower, MD

07/2013 – 10/2018 Assistant Professor, Tenure Track  
Department of Medicine, Division of Hematology/Oncology  
University of Miami Miller School of Medicine, Miami, FL  
Division Chiefs: Joseph Rosenblatt, MD, and C. Albert Lockhart, MD  
Mentor: Jonathan C. Trent, MD, PhD

07/2018 – 10/2018 Co-Director of Phase I Program, Medical Oncology  
University of Miami Miller School of Medicine, Miami, FL

11/2018 – present Associate Professor, Department of Medicine  
Director of Sarcoma Translational Research  
Division of Medical Oncology  
University of Colorado School of Medicine, Aurora, CO  
Division Head: Wells Messersmith, MD

9/2019 – present Deputy Associate Director of Clinical Research  
Director of Investigator-Initiated Trials Committee  
University of Colorado Cancer Center

8/2020 – present Director, Sarcoma Medical Oncology  
University of Colorado School of Medicine, Aurora, CO

### **Hospital, government or other professional positions**

#### Hospital Appointments:

7/2013 – 10/2018 Sylvester Comprehensive Cancer Center  
University of Miami Hospital and Clinics  
University of Miami Hospital  
Jackson Memorial Hospital

11/2018 – present University of Colorado Hospital

#### Non-academic/military Appointments:

N/A

### **Honors, special recognitions and awards**

Alpha Omega Alpha, elected Junior year of Medical School	2005
Gold Humanism Honor Society	2006
Honorary Connie Caplan Fellowship	2011
Sylvester Comprehensive Cancer Center Outstanding Clinical Researcher of the Year	2017

Dolphins Cancer Challenge/University of Miami Heavy Hitter Hero Award	2017
#RedefinePossible WNBA Chicago Sky Women's 2019 Leadership Award	2019
The Life Raft Group GIST Clinician of the Year	2020

### **Membership in professional organizations**

Member, American Association of Cancer Research	2010 – present
Member, Connective Tissue Oncology Society	2010 – present
Member, American Society of Clinical Oncology	2010 – present
Member, Sarcoma Alliance for Research Through Collaboration	2010 – present
Member, Children's Oncology Group	2013 – 2015
Member, National Radiation Group Oncology	2014 – 2018
Member, Society of Immunotherapy for Cancer	2015 – present

### **Major Committee and Service Responsibilities**

#### University of Colorado Cancer Center

Deputy Associate Director for Clinical Research	9/2019 – present
Director, Investigator-Initiated Trials Committee	9/2019 – present
Member, Clinical Incentive Plan Revision Committee	9/2019 – present
Member, Protocol Review and Monitoring System Scientific Review Committee	6/2019 – 9/2019

#### University of Miami, Sylvester Comprehensive Cancer Center

Member, Protocol Review and Monitoring Committee	2015 – 2017
Member, Pharmacy and Therapeutics Committee	2013 – 2017
Member, Fellowship Selection Committee, Medical Oncology	2013 – 2018
Member, Fellowship Selection Committee, Orthopedic Surgery	2013 – 2018
Member, Faculty Recruitment Committees (Breast, Orthopedics, Sarcoma, Immunotherapy)	2015 – 2018

#### American Society of Clinical Oncology

Reviewer, ASCO eLearning Self-Assessment Program	1/2019 to present
Participant, ASCO eLearning Item Writing Workshop	10/2019
Volunteer, Benchmarking Study through Value in Cancer Care Task Force	8/2019 – 11/2019)
Volunteer, ASCO Meeting Publications Editorial Board	10/2019 – present

#### Community Activities

##### Program Leadership

Program Director	5/2020
2020 Life Raft Group GIST Day of Learning Patient Education Program (Virtual)	

Program Director	3/2020
2020 National Leiomyosarcoma Foundation Patient Education Program (Virtual)	

Program Director 10/2020  
2020 National Leiomyosarcoma Foundation International Research Roundtable (Virtual)

Course Director 11/2019  
2019 Mountain States Cancer Conference Aurora, CO

Program Director 09/2016  
Alveolar Soft Part Sarcoma Day of Learning and Research Workshop, Miami, FL.

#### Scientific/Medical Advisory Board Memberships

Desmoid Tumor Research Foundation 03/2019 – present  
The EHE Foundation 07/2017 – present  
National Leiomyosarcoma Foundation 05/2017 – present  
Manny Alvarez Foundation 09/2014 – present  
Angiosarcoma Awareness, Inc. 11/2019 – present

#### Invited Speaker

American Cancer Society Road to Recovery Volunteers Event 10/2019  
Dolphins Cancer Challenge Captain's Lunch 10/2017  
Conquer Cancer Foundation 06/2017  
An Evening to Conquer Cancer, Chicago, IL  
Conquer Cancer Foundation; 03/2017  
Integra Connect Golf Classic, Jupiter, FL  
Conquer Cancer Foundation; 10/2016  
Board of Directors Meeting, Palm Beach, FL

#### **Licensure and board certification**

Diplomate American Board of Internal Medicine  
Internal Medicine (2009 – 2019)  
Medical Oncology (2011 – 2021)

##### Medical Licenses

State of Colorado (09/2018 - 04/2021)  
State of Florida (2013 – 2019)  
State of Maryland (2009 – 2013)

#### **Inventions, intellectual property and patents held or pending**

N/A

#### **Review and referee work**

##### Grant Review Committees

Sylvester Comprehensive Cancer Center Intramural Grant Programs 2016 – 2018  
Florida Academic Cancer Center Alliance Collaborative Proposals 2017  
Desmoid Tumor Research Foundation 2018 – present  
National Leiomyosarcoma Foundation 2018 – present

The EHE Foundation  
CTREC Innovation Grants (University of Colorado Intramural)

2018 – present  
2020

Ad hoc Journal Reviewer:

Molecular Cancer Therapeutics, Oncotarget, Clinical Cancer Research, Cancer, PLoS One, Rare Tumors, Journal of Bone Oncology, Saudi Medical Journal

**Invited extramural lectures, presentations and visiting professorships**

Local

Panel Member, Internal Medicine Interest Group, Johns Hopkins University School of Medicine, Baltimore, MD. November 9, 2011.

GIST 101. The Life Raft Group GIST Day of Learning, Sylvester Comprehensive Cancer Center, Miami, FL. February 9, 2014.

The future of sarcoma therapy. The Life Raft Group GIST Awareness Day, Sylvester Comprehensive Cancer Center, Miami, FL. July 13, 2014.

Beyond MAI: New frontiers in sarcoma treatment. Sylvester Comprehensive Cancer Center Grand Rounds, Miami, FL. September 24, 2014.

The importance of clinical trials for sarcoma patients. Cancer Support Community Greater Miami, Miami FL. January 30, 2015.

GIST 101. The Life Raft Group GIST Day of Learning, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL. May 16, 2015.

New Frontiers in Sarcoma Therapy. Sarcoma Foundation of America/Sylvester Comprehensive Cancer Center Patient Educational Conference, Miami, FL. September 26, 2015.

Gastrointestinal Stromal Tumors – A Model for Precision Medicine in Oncology. Department of Medicine Grand Rounds, University of Miami Miller School of Medicine, Miami, FL. October 7, 2015.

GIST 101. The Life Raft Group GIST Day of Learning, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL. April 3, 2016

Overview of Alveolar Soft Part Sarcoma: Past – Present – Future. Alveolar Soft Part Sarcoma Day of Learning and Research Workshop. Sylvester Comprehensive Cancer Center, Miami, FL. September 23, 2016.

New Frontiers in Sarcoma Treatment. Sarcoma Foundation of America Patient Education Conference, Miami, FL. September 24, 2016.

From Vision to Reality: Deploying the Immune System for Treatment of Sarcoma. Junior Faculty Lecture Series. University of Miami, Miami, FL. February 13, 2017.

Deploying the immune system for treatment of GIST. The Liferaft Group GIST Day of Learning, Miami, FL, March 25, 2017.

Recognizing Autoimmune Toxicities from Immunotherapy in Cancer Patients. University of Miami Department of Medicine Grand Rounds, Miami, FL, October 3, 2017.

Biomarkers in Cancer. Preceptorship in Molecular Pathology: Prognostic and Predictive Roles in Cancer Treatment. Sylvester Comprehensive Cancer Center, Miami, FL. April 26, 2018.

Panel Member, State of GIST: A Clinical Panel of Experts. The Liferaft Group GIST Lifest. Miami, FL. July 14, 2018.

Empowering the immune system in sarcomas: From bedside to bench and back again. University of Colorado Department of Medicine Research and Innovation Conference. Aurora, CO. April 11, 2019.

Empowering the immune system in sarcomas: From bedside to bench and back again. University of Colorado Cancer Center Symposium Series, Aurora, CO. September 19, 2019.

Adoptive cellular therapy: past, present, future. National Clinical Trials Network Annual Retreat. Aurora, CO. November 1, 2019.

Tailoring immunotherapy combinations to improve outcomes in sarcomas. University of Colorado Cancer Center Annual Retreat and Poster Session. Aurora, CO. November 5, 2019.

### Regional

Updates in Sarcoma. *American Society of Clinical Oncology* Annual Meeting Review 2017, Sylvester Comprehensive Cancer Center, Ft. Lauderdale, FL. August 26, 2017.

Basic Principles of Cancer Immunotherapy. *Society for Immunotherapy of Cancer* Advances in Cancer Immunotherapy, Miami, FL. March 10, 2018.

Introduction to Immunotherapy. Broward Oncology Nursing Society Education Day, Pembroke Pines, FL. June 9, 2018.

Updates in Sarcoma: *American Society of Clinical Oncology* Annual Meeting Review 2018, Sylvester Comprehensive Cancer Center, Ft. Lauderdale, FL. June 30, 2018.

What's Next for Cancer Immunotherapy. *Society for Immunotherapy of Cancer* Advances in Cancer Immunotherapy, Denver, CO. March 2, 2019.

What's Next for Cancer Immunotherapy: Beyond PD-1 Blockade. Mountain States Cancer Conference, Aurora, CO. November 8, 2019.

### National

Evidence-based Recommendations for Gastrointestinal Stromal Tumors. Oncology Exchange CME Program, Billings Clinic, Billings, MT. April 29, 2014

Session Co-Chair, Sarcoma Poster Highlights Session, *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL. June 2014.

Management of imatinib side effects. The Life Raft Group Life Fest, Teaneck, NJ. November 9, 2014.

Session Co-Chair, Sarcoma Poster Highlights Session, *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL. June 2015.

Immunotherapy for Sarcomas: Where Do We Go from Here? *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL. June 6, 2016. (Discussant)

The Basics of GIST from the Expert in Layman's Terms. Eighth Annual GIST Summit. GIST Support International, Houston, TX. September 17, 2016.

The Future of Trials in Osteosarcoma. Osteosarcoma Alliance FACTOR Conference, Miami, FL. February 24, 2017.

Early-Phase Immunotherapy, Cellular Therapy, and Vaccine Trials in Sarcoma. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL. June 5, 2017.

Personalized Medicine in Desmoid Fibromatosis: Specific  $\beta$ -catenin Mutations and Responses to Chemotherapy. *Desmoid Tumor Research Foundation* Annual Patient Meeting, Philadelphia, PA. September 23, 2017.

Precision Medicine in Desmoid Fibromatosis: Mutation Phenotypes and Responses to Chemotherapy. *Desmoid Tumor Research Foundation* Research Workshop, Philadelphia, PA. September 24, 2017.

Immunotherapy in Sarcoma: A New Frontier. Davenport Family Endowed Lecturer. University of Arizona Cancer Center, Tucson, AZ. October 23, 2017.

Immunotherapy in Sarcoma: A New Frontier. University of Pennsylvania, Philadelphia, PA. February 21, 2018.

The Promise of Immunotherapy: A Clinician's Perspective. Board of Directors Meeting and All-Hands Employee Meeting. Agenus Bio, Lexington, MA, March 29, 2018.

Enhancing Efficacy of Checkpoint Inhibitors with VEGF Blockade in Soft Tissue Sarcomas. University of Colorado School of Medicine, Aurora, CO. July 16, 2018.

FAQs for Desmoid Tumors. *Desmoid Tumor Research Foundation*, Annual Patient Meeting, Philadelphia, PA. September 22, 2018.

Desmoid Tumors: Understanding Treatment Options in 2019. *Desmoid Tumor Research Foundation* West Coast Regional Patient Meeting, San Francisco, CA. April 13, 2019.

Cytotoxics plus Checkpoint Inhibitors: The Search for Synergy. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL. June 3, 2019. (Discussant)

Harnessing the Immune System in Leiomyosarcoma: From Bedside to Bench and Back Again. *National Leiomyosarcoma Foundation*, International Research Roundtable, Miami, FL. September 14, 2019.

If in doubt, should we cut it out? Unique challenges of intraabdominal desmoid tumors. Joint lecture with Martin McCarter, MD. *Desmoid Tumor Research Foundation* Annual Patient Meeting, Philadelphia, PA. September 21, 2019.

$\beta$ -catenin mutations as predictors of systemic therapy response. *Desmoid Tumor Research Foundation* Annual Research Workshop, Philadelphia, PA. September 22, 2019.

Sarcoma Management. SPECTRUM Conference, Interventional Radiology. Miami Beach, FL. January 19, 2020.

Introduction to EHE and Current Management. SPECTRUM Conference, Interventional Radiology. Miami Beach, FL. January 20, 2020.

Refining the understanding of immune checkpoint blockade in soft tissue sarcoma. *American Society of Clinical Oncology*, Annual Meeting, (Virtual). June 2020. (Discussant)

Imatinib...sunitinib...regorafenib...oh my! The Life Raft Group LifeFest (Virtual). July 11, 2020.

### International

Approach to Progressive Disease in GIST. *New Horizons GIST Meeting*, Sitges, Spain. May 19, 2016.

In Pursuit of a Cure – Current and Future Clinical Trials in GIST. *New Horizons GIST Meeting*, Sitges/Barcelona, Spain. May 19, 2016.

Soft Tissue Sarcomas: Using Precision Medicine to Guide Therapy. *3<sup>rd</sup> International Congress on Molecular Targeting Therapy*, Kibbutz Hagroshrim, Israel. April 28, 2017.

Tailoring checkpoint inhibitor combinations to improve outcomes in sarcomas. Open Education Session: Opportunities and challenges of novel therapies in sarcoma. In conjunction with the *Connective Tissue Oncology Society Annual Meeting*, Tokyo, Japan. November 13, 2019.

Selecting Soft Tissue Sarcoma Patients for Immunotherapy. Forum for Translational Research in Sarcomas (FORTRESS). Essen, Germany. January 23, 2020.

Novel Therapeutic Approaches in Sarcoma - Using the Immune System. Forum for Translational Research in Sarcomas (FORTRESS). Essen, Germany. January 23, 2020. (Session Co-Chair).

## Teaching record

### Didactic: Medical Students

**Preceptor**, Palliative Care Simulation with Johns Hopkins University School of Medicine. Helped to develop and participated in clinical skills workshop for medical students and oncology fellows utilizing standardized patients and clinical scenarios. Scenarios focused on breaking bad news, addressing uncertainties, and discussions of end-of-life and goals of care discussions. (2012).

### Didactic: Graduate Students

**Lecturer**: Principles of Cancer Immunotherapy, in CAB 710, Cancer Biochemistry and Molecular Biology. Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine. (April 26, 2018).

### Didactic: Oncology Fellows

**Lecturer, Fellows Educational Conferences**: University of Colorado (2019 – present)  
Sarcoma 101 (November 5, 2019, and December 13, 2019)

**Leader of Core Curriculum for Sarcoma Modules**: University of Miami (2014 - 2018). Designed and coordinated speakers from pathology, radiation oncology, musculoskeletal radiology, surgical oncology, orthopedic oncology, and medical oncology to cover sarcoma multidisciplinary aspects on a yearly basis. Personally lectured on the following topics:

Chemotherapy for soft tissue sarcoma (2014, 2016, 2018)

GIST 101 (2014)

Chemotherapy for bone sarcomas (2014)

**Chief Fellow**: Johns Hopkins University (2011-2012). Acted as liaison between Fellowship Leadership and First-Year Fellows, providing mentorship and support. Served as representative of fellows at Cancer Center organizational and nursing management meetings. Helped to redesign oncology rotations for housestaff and fellows to meet new ACGME workhours guidelines. Coordinated housestaff call scheduling, moonlighting coverage, Solid Tumor Conference, didactic lecture series. Helped design standardized patient simulation session to assess and evaluate first-year fellows in Medical Oncology communication skills.

### Clinical Teaching: Ward/Clinic Attending Duties



**Inpatient Consulting Attending**, University of Colorado Hospital. Supervision and teaching of oncology fellows, 3 weeks per year (2019-present)

**Inpatient Attending**, University of Miami Hospital Hematology/Oncology Inpatient Service and Consult Service. Supervision and teaching of internal medicine residents, 12 weeks per year (2016 – 2018)

**Inpatient Attending**, Sylvester Comprehensive Cancer Center, Solid Tumor Inpatient Oncology Service. Supervision and teaching of internal medicine residents, 4 weeks per year (2013 – 2016)

**Inpatient Consulting Attending**, Jackson Memorial Hospital. Provided supervision and teaching of oncology fellow, 2 weeks per year (2014 – 2017)

**Fellow Supervision**, ACC East Medical Oncology Clinic, Jackson Medical Systems. Supervision of medical oncology fellows' continuity clinic. 13 4-hour sessions per year (2014 – 2018)

**Fellow/Resident Teaching**, Sylvester Comprehensive Cancer Center sarcoma clinics. Precepted between 1-3 fellows/residents in clinic with me (16 hours per week). (2015 – 2018)

#### Mentoring and Trainees

**Mentor/Supervisor**, Kyle Powers, BS. Translational research in sarcoma immune microenvironment and application of immunotherapy combinations. University of Colorado (1/2020 – present)

**Mentor/Supervisor**, Cristiam Moreno Tellez, MD. Translational research in sarcoma immune microenvironment and application of immunotherapy combinations. Promoted from Volunteer to Research Assistant 1/2020. University of Colorado. (9/2019 – present)

**Supervisor**, Senior Professional Research Assistant, Yupanqui Caldas, PhD. Translational research in sarcoma immune microenvironment and application of immunotherapy combinations. University of Colorado. (4/2019 – 4/2020)

**Research Mentor**, Oncology Fellow, Emily Jonczak, MD. Dual targeting of adenosine receptors with tyrosine kinase inhibitors in solid tumors. University of Miami. Current: Assistant Professor, Sarcoma Program, University of Miami. (7/2018 – 10/2018)

**Research Mentor**, Oncology Fellow, Vaia Florou, MD. Investigating the Role of B Cells in Sarcomas. University of Miami. Current: Assistant Professor, Sarcoma Program, University of Utah Huntsman Cancer Institute. (7/2017 – 10/2018)

**Research Mentor**, Navid Alavi, MD, MPH. Predictors of Response to Chemotherapy in Soft Tissue Sarcomas. Current: Internal Medicine Resident at Howard University Hospital, Washington DC. (2016-2017)

**Physician Committee Member**, PhD dissertation committee, Luyuan Li, BS. Determining anti-tumorigenic activities and mechanisms of IDH1-mutant specific inhibitor on human chondrosarcomas. University of Miami, Miller School of Medicine. Awarded PhD. (2015 – 10/2018)

**Research Mentor**, Internal Medicine Resident, Peter DeMaria, MD (2014-2017), current fellow at NCI; Heath Catoe, MD, PhD, VA Hospitalist, Robert Hsu, MD oncology fellowships. Association of CTNNB1 Mutation Status with Sensitivity to Chemotherapy, University of Miami. (2017 – October 2018)

**Supervisor**, Laboratory Research Associate, Catherine Kim, BS. Direct responsibility and supervision of post-baccalaureate student in laboratory, with continuing support with experimental design, methods training, and analysis/interpretation of data. Johns Hopkins University, (2012 – 2015.) Current –Internal Medicine Residency at University of Illinois COM.

## **Grant support**

### Active, Investigator-Initiated Research

Role: Multi-PI with Eduardo Davila, PhD  
Sponsor: Cancer League of Colorado  
Proposal Title: Toxicity and Biodistribution of CD8 $\alpha$ :MyD88 Engineered Autologous T Cells in Mouse Models of Melanoma and Fibrosarcoma  
Period of Support: 07/1/20 – 6/30/21  
Award: \$60,000

Role: PI  
Sponsor: Sarcoma Foundation of America  
Proposal Title: Boosting Tumor Immunogenicity to Enhance Response to Immune Checkpoint Blockade in Soft Tissue Sarcomas.  
Period of Support: 07/1/20 – 6/30/21  
Award: \$50,000

Role: PI Grant Number: 25A7806  
Sponsor: American Cancer Society Mentored Research Scholar Grant  
Proposal Title: Enhancing efficacy of checkpoint inhibitors with VEGF blockade in sarcoma.  
Period of Support: 11/1/18 – 10/30/22  
Effort: 60%  
Award: \$583,000

Role: PI  
Sponsor: Cancer League of Colorado  
Proposal Title: An open-label, phase II efficacy trial of doxorubicin in combination with dual checkpoint blockade using AGEN1884 and AGEN2034 for advanced or metastatic soft tissue sarcomas.  
Period of Support: Estimated 10/1/19 – 9/30/22  
Award: \$100,000

Role: PI (Investigator-Initiated Trial)  
Sponsor: Agenus, Inc  
Proposal Title: An open-label, phase II efficacy trial of doxorubicin in combination with dual checkpoint blockade using AGEN1884 and AGEN2034 for advanced or metastatic soft tissue sarcomas.  
Period of Support: 1/29/20 – 6/16/24  
Award: \$450,000

### Active, Industry-Sponsored Research

Role: Institutional PI  
Sponsor: Adaptimmune

Proposal Title: A phase 2 single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS).

Period of Support: Estimated 10/1/19 – 9/30/22

Award: Estimated \$450,000

Role: Institutional PI

Sponsor: Advenchen

Proposal Title: Phase III study of AL3818 (anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma.

Period of Support: Estimated 5/1/19 - 3/8/21

Award: contract pending

Role: Institutional PI

Sponsor: Immunocore

Proposal Title: A phase I/II open-label, multi-center study of the safety and efficacy of IMCnyeso, an HLA-A\*0201-restricted, NY-ESO-1- and LAGE-1A-specific soluble T cell receptor and anti-CD3 bispecific molecule, as a single agent in HLA-A\*0201 positive patients with advanced NY-ESO-1 and/or LAGE-1A positive cancer.

Period of Support: Estimated 10/1/19 – 5/1/22

Award: contract pending

Role: Institutional PI

Sponsor: Immunocore

Proposal Title: A phase 1/2 first-in-human study of the safety and efficacy of IMC-C103C as a single agent and in combination with atezolizumab in HLA-A\*0201-positive patients with advanced MAGE-A4-positive cancer.

Period of Support: Estimated 3/1/2022 – 3/1/2025

Role: Institutional PI

Sponsor: Sound Biologics

Proposal Title: A phase 1, open-label, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PSB205 in patients with relapsed/refractory solid tumors.

Period of Support: Estimated 1/1/2020 – 1/1/2022

#### Prior, Investigator-Initiated Research

Role: PI

Sponsor: Desmoid Tumor Research Foundation

Proposal Title: Correlation of CTNNB1 mutation status with chemotherapy response by MRI in patients with desmoid tumors

Period of Support: 3/1/16 – 12/31/18, effort (3%)

Award: \$25,000 first year, additional \$25,000 for year 2.

Role: PI – Investigator Initiated Trial

Sponsor: Merck

Proposal Title: A phase II clinical trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas

Period of Support: 3/1/16 – 3/22/20

Award: \$975,000, effort (1%)

Role: PI – Investigator Initiated Trial  
Sponsor: Sylvester Comprehensive Cancer Center  
Proposal Title: A phase I trial of dendritic cell vaccination with and without inhibition of myeloid derived suppressor cells by gemcitabine pre-treatment for children and adults with sarcoma.  
Period of Support: 7/1/2015 – 7/1/2018  
Award:

Role: PI – Investigator Initiated Trial  
Sponsor: Sylvester Comprehensive Cancer Center Clinical Trial Acceleration Grant  
Proposal Title: A phase II clinical trial of combination axitinib plus pembrolizumab for advanced soft tissue sarcomas.  
Period of Support: 9/1/2015 – 12/31/2017  
Award: \$100,000, effort (10%)

Role: PI  
Sponsor: Stanley J. Glaser Foundation Research Award  
Proposal Title: Identification of immune cells and antigen targets in soft tissue sarcoma patients treated with combination axitinib plus pembrolizumab.  
Period of Support: 6/1/17 – 5/31/18  
Award: \$42,000, Effort (5%)

Role: PI  
Sponsor: American Cancer Society Institutional Research Grant Program  
Proposal Title: Profiling tumor-infiltrating and circulating lymphocytes in sarcoma patients treated with alternating axitinib, a pan-VEGF inhibitor, and pembrolizumab, an anti-PD1 monoclonal antibody.  
Period of Support: 12/1/2015 – 5/31/2018  
Award: \$45,000, effort (5%)

Role: PI  
NIH Loan Repayment Program  
Proposal Title: The role of RNA helicase DDX3 in Ewing's sarcoma stem cells.  
Period of Support: 7/1/12 through 6/30/15  
Amount: \$105,000

Role: PI  
Alpha Omega Alpha Postgraduate Award 2012  
Proposal Title: The role of RNA helicase DDX3 in Ewing's sarcoma.  
Period of Support: 10/1/12 through 9/30/13  
Amount: \$2,000

Role: PI  
Conquer Cancer Foundation/ASCO Young Investigator Award 2012  
Sponsor: WWW (QuadW) Foundation, Inc.  
Proposal Title: The role of RNA helicase DDX3 in Ewing's sarcoma stem cells  
Period of Support: 7/1/12 through 6/30/13  
Amount: \$50,000

Application ID: 2T32CA009071-31  
Role: Trainee  
Proposal Title: Molecular targets for cancer detection and treatment training grant.

Period of Support: 8/1/11 through 8/1/12  
Project Period Begin/End Date: 09/15/1979-06/30/2016  
PIs: William G. Nelson, M.D., Ph.D /Ben Ho Park, M.D., Ph.D

Prior, Industry-Sponsored Research

Role: Institutional PI  
Sponsor: Advenchen  
Proposal Title: Phase III study of AL3818 (anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma  
Period of Support: 3/9/17 - 3/8/21

Role: Institutional PI  
Sponsor: Agenus, Inc.  
Proposal Title: A phase 1 / 2, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumors, with expansion to second-line cervical cancer.  
Period of Support: 3/23/17 – 3/22/21

Role: Institutional PI  
Sponsor: Agenus, Inc.  
Proposal Title: A phase 1 study of safety, tolerability and feasibility of AutoSynVax vaccine as a single agent in subjects with advanced cancer.  
Period of Support: 1/20/2017 to 1/19/21

Role: Institutional PI  
Sponsor: Agenus, Inc.  
Proposal Title: A phase 1 open-label, multicenter study to evaluate the safety, PK, and PD of an anti-CTLA4 human monoclonal antibody (AGEN1884) and to estimate the MTD in subjects with advanced or refractory cancer.  
Period of Support: 6/17/2016 to 6/16/20

Role: Institutional PI  
Sponsor: Daiichi Sankyo  
Proposal Title: Protocol PLX108-10 - A double-blind, randomized, placebo-controlled phase 3 study of orally administered PLX3397 in patients with pigmented villonodular synovitis or giant cell tumor of the tendon sheath.  
Period of Support: 7/6/15 – 7/5/19

Role: Institutional PI  
Sponsor: Novartis Pharmaceuticals  
Proposal Title: A Phase II randomized, double-blind, placebo controlled study to assess safety, tolerability and effect on tumor size of MCS110 in patients with pigmented villonodular synovitis (PVNS)  
Period of Support: 6/8/12 – 6/7/17

Role: Institutional PI  
Sponsor: Adaptimmune LLC  
Proposal Title: ADP-04511- A pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259T in HLA-A2+ patients with synovial sarcoma.  
Period of Support: 3/21/16 – 3/20/20

Role: Institutional PI  
 Sponsor: Arqule, Inc  
 Proposal Title: ARQ 197-299: An extension protocol for subjects who were previously enrolled in other ARQ 197 protocols.  
 Period of Support: 11/19/15 – 10/4/16

Role: Institutional PI  
 Sponsor: Millennium Pharmaceuticals  
 Proposal Title: C14019 - Pharmacokinetics of oral alisertib (MLN8237) in adult patients with advanced solid tumors or relapsed/refractory lymphoma with varying degrees of hepatic function.  
 Period of Support: 4/7/15 – 4/6/19

Role: Institutional PI  
 Sponsor: Celgene  
 Proposal Title: AG221-C-003 - A phase 1/2, multicenter, open-label, dose-escalation study of AG-221 in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma, that harbor an IDH2 mutation.  
 Period of Support: 5/1/15 – 4/30/18

## Bibliography

### Citation Metrics

	All	Since 2014
Google Scholar Citations	418	413
h-index	13	13
i10-index	13	13

### Peer-Reviewed Journal Articles

1. Scannell C, Pederson E, Mosher J, Krook M, Nicholls L, Wilky BA, Loeb D, Lawlor E. [LGR5 is expressed by Ewing sarcoma and potentiates Wnt/ \$\beta\$ -catenin signaling.](#) Front Oncol, 2013, 3:81.
2. Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. [A dose finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma.](#) Int J Cancer, 2013, 133(4): 997-1005.
3. Wilky BA, Montgomery E, Guzzetta A, Ahuja N, Meyer C. [Extrathoracic location and “borderline” histology are associated with recurrence of solitary fibrous tumors after surgical resection.](#) Ann Surg Oncol 2013, 20(13) 4080-9.
4. Trucco MM, Awad O, Wilky BA, Goldstein SD, Huang R, Walker RL, Shah P, Katuri V, Gul N, Zhu YJ, McCarthy EF, Paz-Priel I, Meltzer PS, Austin CP, Xia M, Loeb DM. [A Novel Chordoma Xenograft Allows In Vivo Drug Testing and Reveals the Importance of NF- \$\kappa\$ B Signaling in Chordoma Biology.](#) PLOS One, 2013. 8(11): e79950. PMID: PMC3819300.
5. Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ, Keller C. [Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma.](#) PLOS Genetics, 2014. 10(1):e1004107.

6. Wilky BA, Rudek M, Ahmed S, Laheru D, Cosgrove D, Donehower R, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Buckley G, Womack C, Azad NS. [A phase I trial of vertical inhibition of IGF signaling using cixutumumab, an anti-IGF1-R antibody, and selumetinib, a MEK 1/2 inhibitor, in advanced solid tumors.](#) Br J Cancer, 2015. 112(1):24-31.
7. Li L, Paz AC, Wilky BA, Johnson B, Rosenberg A, Bodamer O, Trent JC. [Treatment with a small molecule IDH1 inhibitor inhibits tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in IDH-mutant chondrosarcoma cells.](#) PLOS One. 2015 Sep;10(9):e0133813.
8. Wilky BA, Kim C, McCarty G, Montgomery E, Kammers K, DeVine L, Cole RN, Raman V, Loeb DM. [RNA Helicase DDX3: A novel therapeutic target in Ewing sarcoma.](#) Oncogene, 2016. 35(20):2574-83.
9. Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R. [Growing Pains: A Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship.](#) J Cancer Educ. 2016. 32(3):496-502.
10. Sheth PJ, del Moral S, Wilky BA, Trent JC, Cohen J, Rosenberg AE, Temple HT, Subhawong TK. [Desmoid Fibromatosis: MRI features of response to systemic therapy.](#) Skeletal Radiol. 2016. 45(1):1365-73.
11. Upadhyaya SA, McGee R, Wilky BA, Broniscer A. [Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.](#) Pediatr Blood Cancer. 2018. 65(7):e27030.
12. Ramey S, Yechieli RL, Zhao W, Kodiyan J, Asher D, Chienea F, Patel V, Reis I, Wang L, Wilky BA, Subhawong TK, Trent JC. [Limb-sparing surgery plus radiotherapy results in superior survival: An analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER.](#) Cancer Med. 2018. 7(9):4228-4239.
13. Espejo AP, Ramdial JL, Wilky BA, Kerr DA, Trent JC. [A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas.](#) Rare Tumors. 2018. 10:2036361318787626.
14. Khazeni K, LaBove H, Paulus E, Wilky BA, Chim H, Pearson JM, Rosenberg AE, Yakoub D. [Myoepithelial carcinoma or epithelioid sarcoma - a rare diagnosis with poor prognosis. A case report and review of literature.](#) Int J Surg Case Rep. 2018. 49:239-243.
15. Trucco MM, Meyer CF, Thornton KA, Shah P, Chen AR, Wilky BA, Carrera-Haro MA, Boyer LC, Ferreira MF, Shafique U, Powell JD, Loeb DM. [A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas.](#) Clin Sarcoma Res. 2018 Nov 5; 8:21.
16. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder E, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. [Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft part sarcoma: a single-arm, phase 2 trial.](#) Lancet Oncol. 2019. 20(6):837-848.
17. Yu-Cherng CC, Mahan J, Subhawong TK, Wilky BA, Breto AL, Diwanji T, Yechieli R, Stoyanova R. [Quantitative imaging features of habitats in soft tissue sarcomas are associated with treatment response: A pilot study.](#) Cancer Stud Ther J. 2019. 4(3):1-6.
18. Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA. [Angiosarcoma patients treated with immune checkpoint inhibitors: A case series of seven patients from a single institution.](#) J Immunother Cancer. 2019. 7(1):213.

19. Disel O, Madison R, Abhishek K, Chung, JH, Matos AO, Trabucco SE, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, **Wilky B**, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM. [The pan-cancer landscape of co-amplification of the tyrosine kinases KIT/KDR/PDGFR \$\alpha\$](#) . *Oncologist*. 2020. 25(1):e39-e47.
20. Kerr DA, Pinto A, Subhawong TK, **Wilky BA**, Schlumbrecht MP, Antonescu CR, Nielsen P, Rosenberg AE. [Pericytoma with t\(7;12\) and ACTB-GLII fusion: Reevaluation of an unusual entity and its relationship to the spectrum of GLII fusion-related neoplasms](#). *Am J Surg Pathol*. 2019. 43(12):1682-1692.
21. Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, **Wilky B**, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. [Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma](#). *J Immunother Cancer*. 2019. 7(1):276.
22. Li L, Hu X, Eid JE, Rosenberg AE, **Wilky BA**, Ban Y, Sun X, Galoian K, DeSalvo J, Yue J, Chen XS, Blonska M, Trent JC. [Mutant IDH1 depletion downregulates integrins and impairs chondrosarcoma growth](#). *Cancers*. 2020. 12(1):E141.
23. Kerr DA, Brcic I, Perez JAD, Shih A, **Wilky BA**, Pretell-Mazzini J, Subhawong TK, Nielsen GP, Rosenberg AE. Immunohistochemical characterization of giant cell tumor of bone treated with denosumab: Support for osteoblastic differentiation. *Am J Surg Pathol*. (*In press*)
24. Subhawong TK, Feister K, Sweet K, Alperin N, Rosenberg AE, Trent JC, **Wilky BA**. Extra-abdominal Desmoid Tumor MRI Radiomics in Assessing Systemic Treatment Response. *Radiology*. (*Submitted*)

#### Invited Book Chapters

1. Jonczak E, **Wilky BA**. Alveolar soft part sarcoma. In: *Sarcomas: Evidence-Based Diagnosis and Management*. Trent JC, Rosenberg AE, Delaney T, Pollack R (eds). (*In press*)
2. Florou V, **Wilky BA**, Rosenblatt JD, Zhang Y. B Cells in the Tumor Microenvironment. In: *Cancer Immunotherapy Principles and Practice*. Kirkwood J, Boyiadzis M, Whiteside T (eds). McGraw-Hill. (*In Press*)
3. Florou V, **Wilky BA**. Part I: The Immune Sarcoma Microenvironment: 3. Regulatory T Cells. In: *Immunotherapy of Sarcoma*. D'Angelo S, Pollack S (eds). Springer Nature. 2019.

#### Invited Articles and Reviews

1. **Wilky BA**, Loeb DM. [Beyond Palliation: Therapeutic Applications of <sup>153</sup>Samarium-EDTMP](#). *Clin Exp Pharmacol*, 2013, 3:131. doi: 10.4172/2161-1459. PMID: PMC4319527.
2. **Wilky BA**, Meyer CF, Trent JC. [Pazopanib in sarcomas: Expanding the PALETTE](#). *Curr Opin Oncol*. 2013, 25(4):373-8. PMID: PMC4090026.
3. **Wilky BA**, Goldberg JM. [Immunotherapy in sarcoma: a new frontier](#). *Discov Med*, 2014, 17(94):201-6.



4. Tinoco G, Wilky BA, Paz-Mejia A, Rosenberg A, Trent JC. [The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.](#) Am Soc Clin Oncol Educ Book, 2015. 35:e648-55.
5. Subhawong TK, Wilky BA. [Value added: Functional MR Imaging in Management of Bone and Soft Tissue Sarcomas.](#) Curr Opin Oncol, 2015. 27(4):323-31.
6. Tan Y, Trent JC, Wilky BA, Kerr DA, Rosenberg AE. [Current status of immunotherapy for Gastrointestinal Stromal Tumor.](#) Cancer Gene Ther, 2017. 24(3):130-133.
7. Wilky BA and Goldberg JM. [From vision to reality: Deploying the immune system for treatment of sarcoma.](#) Discov Med, 2017. 23(124):61-74.
8. Wilky BA, Jones RL, Keedy VL. [The current landscape of early drug development for patients with sarcoma.](#) Am Soc Clin Oncol Educ Book, 2017. 37:807-810.
9. Florou V, Wilky BA, Trent JC. [Latest advances in adult gastrointestinal stromal tumors.](#) Future Oncol, 2017. 113(24):2183-2193.
10. Florou V, Wilky BA. [Current and future directions for angiosarcoma therapy.](#) Curr Treat Options Oncol. 2018. 19(3):14.
11. Alavi SN, Florou V, Tinoco G, Trent JC, Wilky BA. [A precision medicine approach in sarcomas: Identification of patients who may benefit from earlier pazopanib.](#) Discov Med. 2018. 25(137):131-144.
12. Sebio A, Wilky BA, Keedy VL, Jones RL. [The current landscape of early drug development for patients with sarcoma in the immunotherapy era.](#) Future Oncol. 2018. 14(12):1197-1211.
13. Ezuddin NS, Pretell-Mazzini J, Yechieli RL, Kerr DA, Wilky BA, Subhawong TK. [Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy.](#) Skeletal Radiol. 2018. 47(12):1595-1606.
14. Wilky BA. [Immune Checkpoint Inhibitors: The Linchpins of Modern Immunotherapy.](#) Immunol Rev. 2019. 290(1):6-23.
15. Hall F, Villalobos VM, Wilky B. [Future Directions in Soft Tissue Sarcoma Treatment.](#) Curr Probl Cancer. 2019. 43(4):300-307.
16. Florou V, Trent JC, Wilky BA. [Precision Medicine in Gastrointestinal Stromal Tumors.](#) Discov Med. 2019. 28(155):267-276.
17. Florou V, Wilky BA. Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Annals of Transl Med. (*Submitted*)

#### Selected Online Media

1. Wilky BA and Villalobos VM. [Emerging Role for Precision Therapy Through Next-Generation Sequencing for Sarcomas.](#) JCO Precision Oncology. Published online October 19, 2018.
2. Interview with Kaplan, Debbie Abrams. [VEGFR Targeted Therapies and Combinations Emerge for the Treatment of Sarcomas.](#) Targeted Oncology. 7/1/2019.
3. Interview with Tordello, Carolyn. [A conversation with Breelyn Wilky, MD.](#) The Life Raft Group. 3/2019.
4. [Breakthroughs Save Lives.](#) Conquer Cancer Foundation. 4/2019.
5. Wilky BA and Agulnik M. [ASCO Tumor Boards: Gastrointestinal Stromal Tumor.](#) 2018.

6. Interview with Laviolette, Julie Landry. [Most of her sarcoma tumors melted away with this clinical trial treatment.](#) *Miami Herald*. 5/23/18.
7. Levitan D. [Axitinib/Pembrolizumab shows promising results in Alveolar Soft-Part Sarcoma.](#) Cancer Network. 11/10/17.
8. Wilky BA. [The fifth pillar of cancer treatment: Is it time to explore immunotherapy for GIST?](#) *The GIST and Sarcoma Journal*, 2016. 3(4):78-83.
9. Sharda, Monika. [Conquering Sarcoma with Clinical Research: A doctor and her patient are paving the way with support from the Conquer Cancer Foundation.](#) *ASCO Connection*. 10/19/2017.
10. Interview with Connelly, Shannon. [Immunotherapy Agents Emerging as Key Players in Sarcoma.](#) *OncLive*. 12/15/2016.
11. Interview with Connelly, Shannon. [New Agents, Targets Continue to Emerge in Sarcoma, Cementing Role for Immunotherapy.](#) *Targeted Oncology*. 11/28/2016.
12. Trent JC, Wilky BA. [Treating Bone and Soft Tissue Sarcomas.](#) *OncLive*. 10/16/2015.
13. Wilky, BA. Personal Blog: [Stories of a Sarcoma Medical Oncologist.](#)
14. Wilky BA. ASCO Daily News: [Expert Perspective on ASCO20 Sarcoma Research.](#)

#### Scientific Abstracts

1. Aggrecan surrounding collagen network in cartilage matrix moderates effects of reactive oxygen species on collagen degradation. *UMDNJ-Robert Wood Johnson Medical School Research Day*, Piscataway, NJ, 2003. Poster.
2. Aggrecan protects cartilage collagen matrix from chondrocyte-derived reactive oxygen radical damage. *American College of Rheumatology*, Annual Scientific Meeting, San Diego, CA, 2005. Poster.
3. Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL 2008. Poster.
4. Extrathoracic solitary fibrous tumors are more likely to exhibit high-risk pathologic features and recur following resection. *Connective Tissue Oncology Society*, Annual Meeting, Chicago, IL, 2011. Poster.
5. Establishment of a chordoma xenograft and in vivo testing of compounds identified by high-throughput screening. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, 2012. Poster.
6. Establishment of a chordoma xenograft and in vivo testing of compounds identified by high-throughput screening. *American Association of Cancer Research*, Annual Meeting, Washington, DC, 2012. Poster.
7. RNA helicase DDX3: A novel therapeutic target in Ewing's sarcoma. *Johns Hopkins University Fellow's Research Day*, Baltimore, MD, May 2012. Poster.
8. RNA helicase DDX3: A novel therapeutic target in Ewing's sarcoma. *European Science Foundation Research Conference on Molecular Biology and Innovative Therapies of Childhood Sarcomas*, Warsaw, Poland, October 2012. Poster.

9. RNA helicase DDX3: A novel therapeutic target in sarcoma. *Connective Tissue Oncology Society*, Annual Meeting, Prague, Czech Republic, November 2012. Poster.
10. A Phase I study determining the safety and tolerability of combination therapy with Pazopanib, a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer, cholangiocarcinoma, and soft tissue sarcoma. *AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics*, Boston, MA, October 2013. Poster.
11. A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors. *AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics*, Boston, MA, October 2013. Poster.
12. RK-33, a small molecule DDX3 inhibitor, enhances radiosensitivity of bone sarcoma cell lines. *Connective Tissue Oncology Society*, Annual Meeting, New York City, NY, October 2013. Poster.
13. RNA helicase DDX3 – a novel therapeutic target in sarcoma. *AACR Special Conference: Pediatric Cancer at the Crossroads: translating Discovery into Improved Outcomes*. San Diego, CA, November 2013. Poster.
14. MCS110, an anti-CSF-1 antibody, for the treatment of pigmented villonodular synovitis (PVNS). *Connective Tissue Oncology Society*, Annual Meeting, Berlin, Germany, October 2014. Poster.
15. Evaluation of IDH mutation, IDH1 inhibition and 2-hydroxyglutarate in human chondrosarcoma cell lines and patient plasma. *Connective Tissue Oncology Society*, Annual Meeting: Berlin, Germany, October 2014. Poster.
16. MRI features of response in the systemic therapy of aggressive fibromatosis. *Connective Tissue Oncology Society*, Annual Meeting: Berlin, Germany, October 2014. Poster.
17. Inhibition of RNA helicase DDX3 disrupts translation of protein targets critical for sarcoma cell physiology. *Connective Tissue Oncology Society*, Annual Meeting, Berlin, Germany, October 2014. Poster.
18. RNA helicase DDX3 is a novel therapeutic target for Ewing sarcoma. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2015. Poster.
19. A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2015. Poster.
20. Decreased fractal lacunarity reflects giant cell tumor response to denosumab. *Society of Skeletal Radiology*, Annual Meeting, New Orleans, LA, March 2016. Poster.
21. Panobinostat and carfilzomib cytotoxicity in IDH-mutant human chondrosarcoma. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2016. Poster.
22. A phase 2 clinical trial of concurrent axitinib and pembrolizumab in subjects with advanced ASPS and other soft tissue sarcomas. *Connective Tissue Oncology Society*, Annual Meeting, Lisbon, Portugal, November 2016. Poster.
23. Feasibility of volumetric ADC mapping to tumor habitats derived from dynamic contrast enhanced MRI in soft tissue sarcomas. *Connective Tissue Oncology Society*, Annual Meeting, Lisbon, Portugal, November 2016. Poster.
24. A phase I trial of autologous dendritic cell vaccination with and without gemcitabine-mediated inhibition of myeloid derived suppressor cells for children and adults with sarcoma.

- Connective Tissue Oncology Society*, Annual Meeting, Lisbon, Portugal, November 2016. Poster.
25. A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743). *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2017. Podium, co-author.
  26. Factors impacting contemporary management of high-grade extremity sarcoma: An analysis of 12,020 patients. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2017. Abstract 11017, Poster Discussion, co-author.
  27. Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2017. Poster.
  28. Impact of local treatment modalities on survival for patients with high-grade extremity soft-tissue sarcomas: An analysis of 2,937 patients. *Connective Tissue Oncology Society*, Annual Meeting, Maui, HI, November 2017. Poster.
  29. Open label non-randomized multi-cohort pilot study of NY-ESO-1 SPEAR T-cells in HLA-A2+ patients with synovial sarcoma (NCT01343043). *Connective Tissue Oncology Society*, Annual Meeting, Maui, HI, November 2017. Podium, co-author.
  30. Antitumor activity of axitinib plus pembrolizumab in a phase II trial for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas. *Connective Tissue Oncology Society*, Annual Meeting, Maui, HI, November 2017. Podium.
  31. The RNA helicase, DDX3, modulates DNA damage repair in Ewing sarcoma. *American Association of Cancer Research*, Annual Meeting, Chicago, IL, April 2018. Abstract 4170. Poster.
  32. Frequency of genomic biomarkers of response to immunotherapy in sarcoma. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2018. Abstract 11579. Poster.
  33. A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2018. Abstract 11547. Poster.
  34. Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): Analysis of 152 patients. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2018. Abstract 11539. Poster.
  35. Phase 1 open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2018. Abstract 3075. Poster.
  36. Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2018. Abstract 3086. Poster.
  37. Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer. *European Society of Medical Oncology*, Annual Meeting, Munich, Germany, October 2018. Abstract 1158P. Poster (co-author).

38. Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma. *CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival*, New York, NY, October 2018. Abstract A007.
39. Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab. *Society of Immunotherapy for Cancer*, Annual Meeting, Washington, DC, November 2018. Poster.
40. Novel therapy with 103PD-directional brachytherapy device for recurrent soft tissue sarcomas: Safety and early postoperative outcomes. *Connective Tissue Oncology Society*, Annual Meeting, Rome, Italy, November 2018. Poster (co-author).
41. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with sarcoma treated with immunotherapy. *Connective Tissue Oncology Society*, Annual Meeting, Rome, Italy, November 2018. Poster (co-author).
42. Safety and efficacy of olaratumab added to doxorubicin-based combination chemotherapy in the treatment of advanced soft-tissue sarcoma (STS). *Connective Tissue Oncology Society*, Annual Meeting, Rome, Italy, November 2018. Poster (co-author).
43. Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): Analysis of 184 patients. *Connective Tissue Oncology Society*, Annual Meeting, Rome, Italy, November 2018. Podium (co-author).
44. Frameshift mutations (Fsinde) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis. *American Society of Clinical Oncology*, Annual Meeting, Chicago, IL, June 2019. Poster (co-author).
45. Safety and efficacy of immune checkpoint inhibitors in patients with angiosarcoma. *Connective Tissue Oncology Society*, Annual Meeting, Tokyo, Japan, November 2019. Poster (Co-author).
46. Phase I Study of DCC-3014 to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with malignant solid and diffuse-type tenosynovial giant cell tumor. *Connective Tissue Oncology Society*, Annual Meeting, Tokyo, Japan, November 2019. Poster.